Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

BACKGROUND: Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments. METHODS: Patients with ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Bratt, O, Häggman, M, Ahlgren, G, Nordle, Ö, Björk, A, Damber, J-E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768463/
https://www.ncbi.nlm.nih.gov/pubmed/19755981
http://dx.doi.org/10.1038/sj.bjc.6605322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768463/
https://www.ncbi.nlm.nih.gov/pubmed/19755981
http://dx.doi.org/10.1038/sj.bjc.6605322

Ejemplares similares